Sargent Investment Group LLC Buys 51,699 Shares of Cytosorbents Co. (NASDAQ:CTSO)

Sargent Investment Group LLC raised its stake in Cytosorbents Co. (NASDAQ:CTSO) by 4.1% during the 4th quarter, Holdings Channel reports. The fund owned 1,308,747 shares of the medical research company’s stock after acquiring an additional 51,699 shares during the period. Sargent Investment Group LLC’s holdings in Cytosorbents were worth $1,453,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Skylands Capital LLC raised its holdings in Cytosorbents by 5.4% in the 3rd quarter. Skylands Capital LLC now owns 2,944,670 shares of the medical research company’s stock valued at $5,536,000 after acquiring an additional 151,200 shares during the period. Raymond James & Associates acquired a new position in shares of Cytosorbents during the 4th quarter worth approximately $56,000. Finally, Chicago Partners Investment Group LLC grew its position in shares of Cytosorbents by 84.0% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 36,358 shares of the medical research company’s stock worth $67,000 after purchasing an additional 16,598 shares in the last quarter. 32.87% of the stock is owned by institutional investors.

Cytosorbents Stock Up 1.2 %

Shares of NASDAQ CTSO traded up $0.01 during trading hours on Friday, hitting $0.82. 96,079 shares of the stock were exchanged, compared to its average volume of 89,447. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.51 and a current ratio of 1.77. The company’s fifty day simple moving average is $0.93 and its two-hundred day simple moving average is $1.16. Cytosorbents Co. has a 1-year low of $0.78 and a 1-year high of $4.29.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, March 14th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. The business had revenue of $8.67 million for the quarter, compared to analyst estimates of $9.29 million. Cytosorbents had a negative net margin of 78.43% and a negative return on equity of 120.24%. Analysts forecast that Cytosorbents Co. will post -0.36 EPS for the current fiscal year.

Analyst Ratings Changes

CTSO has been the topic of a number of analyst reports. HC Wainwright restated a “neutral” rating and set a $1.00 target price on shares of Cytosorbents in a research report on Friday, March 15th. StockNews.com initiated coverage on shares of Cytosorbents in a research report on Wednesday. They set a “hold” rating on the stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.